Cytokine Hemadsorption Therapy in Critically Ill Patients Who Have no Microbiological Findings and Develop Vasoplegic Shock
Conditions
Keywords
vasoplegic shock, cytokine hemadsorption, hemodynamics, mortality, cytokine storm
Brief summary
Observation of the effects of cytokine adsorbent hemadsorption therapy on hemodynamics and mortality in critically ill patients who developed vasoplegic shock due to hyperinflammation without microbiological findings in the intensive care unit.
Detailed description
Observation of the effects of cytokine adsorbent hemadsorption therapy on hemodynamics and mortality in critically ill patients who developed vasoplegic shock due to hyperinflammation without microbiological findings and met the inclusion criteria in the Intensive Care Unit between 01.08.2023 and 01.02.2024
Interventions
PROCEDUREcytokine hemadsorption therapy
Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
Sponsors
Hakan Küçükkepeci
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* C-reactive protein (CRP) ≥ 100 mg/l * Procalcitonin (PCT) \< 2 ng/l * Patients aged 18-80 years who were treated with cytokine adsorption due to vasoplegic shock
Exclusion criteria
* Patients under 18 years of age * Patients with suspected or proven bacterial cause of vasoplegic shock. * Those who did not approve to participate in the study * Patients without vasoplegic shock * Patients with CRP \< 100 mg/l, PCT ≥ 2 μg/L
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time to resolution of vasoplegic shock within days. | From enrollment to the end of treatment at 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin 1 beta level on day 1 | one day |
| Interleukin 10 level on day 1 | one day |
| Interleukin 6 level on day 1 | one day |
| TNF - α level on day 1 | one day |
| Interleukin 1 beta level on day 3 | 3 days |
| 7-day mortality | 7 days |
| mortality until discharge from hospital | From enrollment to the end of treatment at 12 weeks |
| Interleukin 6 level on day 3 | 3 days |
| TNF - α level on day 3 | 3 days |
| mechanical ventilation need and duration | From enrollment to the end of treatment at 12 weeks |
| duration of treatment in the intensive care unit | From enrollment to the end of treatment at 12 weeks |
| dose of catecholamine | From enrollment to the end of treatment at 12 weeks |
| Interleukin 10 level on day 3 | 3 days |
Countries
Turkey (Türkiye)
Outcome results
None listed